stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) EV/FCF
As of 4 November 2026, Indivior Pharmaceuticals Inc. (SUPN) trades at a EV/FCF of 138×. Over the past ten years it has ranged from −276× (January 2023) to 333× (January 2025); the current reading is higher than 97% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −48.5× | — |
| FY2024 | 331× | — |
| FY2023 | −5.5× | — |
| FY2022 | −237× | — |
| FY2021 | 4.9× | — |
| FY2020 | −2.3× | — |
| FY2019 | −3.0× | — |
| FY2018 | 1.0× | (93.40%) |
| FY2017 | 15.1× | 132.09% |
| FY2016 | 6.5× | (9.67%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 169× | — |
| Jun 2026 | −45.8× | — |
| Mar 2026 | −21.2× | — |
| Dec 2025 | −48.5× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −158× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −21.7× |
| LNTH Lantheus Holdings, Inc. compare | 16.6× |
| LQDA Liquidia Corporation compare | 25.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 32.2× |
| ALKS Alkermes plc compare | 36.0× |
| HIMS Hims & Hers Health, Inc. compare | 73.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
| SUPN Indivior Pharmaceuticals Inc. | 138× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement